Unicycive Therapeutics Inc (NASDAQ: UNCY)’s stock price has soared by 7.87 in relation to previous closing price of 0.68. Nevertheless, the company has seen a loss of -18.33% in its stock price over the last five trading days. globenewswire.com reported 2025-06-10 that – The U.S. Food and Drug Administration (FDA) identified deficiencies at a third-party manufacturing vendor – FDA to provide final decision by PDUFA action date of June 28, 2025 LOS ALTOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY or the “Company”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced an update on its New Drug Application (NDA) for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.
Is It Worth Investing in Unicycive Therapeutics Inc (NASDAQ: UNCY) Right Now?
The 36-month beta value for UNCY is also noteworthy at 2.00. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for UNCY is 100.03M, and at present, short sellers hold a 0.36% of that float. The average trading volume of UNCY on June 16, 2025 was 2.66M shares.
UNCY’s Market Performance
UNCY’s stock has seen a -18.33% decrease for the week, with a 33.49% rise in the past month and a 26.51% gain in the past quarter. The volatility ratio for the week is 31.08%, and the volatility levels for the past 30 days are at 14.36% for Unicycive Therapeutics Inc The simple moving average for the last 20 days is 12.27% for UNCY’s stock, with a simple moving average of 29.59% for the last 200 days.
Analysts’ Opinion of UNCY
Many brokerage firms have already submitted their reports for UNCY stocks, with Guggenheim repeating the rating for UNCY by listing it as a “Buy.” The predicted price for UNCY in the upcoming period, according to Guggenheim is $6 based on the research report published on April 21, 2025 of the current year 2025.
Piper Sandler, on the other hand, stated in their research note that they expect to see UNCY reach a price target of $9. The rating they have provided for UNCY stocks is “Overweight” according to the report published on April 04th, 2024.
UNCY Trading at 19.07% from the 50-Day Moving Average
After a stumble in the market that brought UNCY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.18% of loss for the given period.
Stock Fundamentals for UNCY
The total capital return value is set at -2.74. Equity return is now at value -2355.27, with -52.73 for asset returns.
Based on Unicycive Therapeutics Inc (UNCY), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -56.61. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -858.39.
Currently, EBITDA for the company is -36.23 million with net debt to EBITDA at 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.64.
Conclusion
In summary, Unicycive Therapeutics Inc (UNCY) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
